©The Author(s) 2026.
World J Gastroenterol. Jan 21, 2026; 32(3): 114176
Published online Jan 21, 2026. doi: 10.3748/wjg.v32.i3.114176
Published online Jan 21, 2026. doi: 10.3748/wjg.v32.i3.114176
Table 2 Achievement of sustained virologic response according to treatment in hepatitis C virus mono-infected and human immunodeficiency virus/hepatitis C virus co-infected groups, n (%)
| Not achieved | Achieved | |
| All treated | ||
| Before IPTW | ||
| HCV mono-infection (n = 741) | 49 (6.6) | 692 (93.4) |
| HIV/HCV co-infection (n = 86) | 16 (18.6) | 70 (81.4) |
| P value | < 0.001 | |
| After IPTW | ||
| HCV mono-infection (n = 741) | 49 (6.6) | 692 (93.4) |
| HIV/HCV co-infection (n = 86) | 11 (13.1) | 75 (86.9) |
| P value | 0.114 | |
| Treated with Peginterferon plus ribavirin | ||
| Before IPTW | ||
| HCV mono-infection (n = 212) | 42 (19.8) | 170 (80.2) |
| HIV/HCV co-infection (n = 30) | 12 (40.0) | 18 (60.0) |
| P value | 0.024 | |
| After IPTW | ||
| HCV mono-infection (n = 212) | 42 (19.8) | 170 (80.2) |
| HIV/HCV co-infection (n = 30) | 13 (42.9) | 17 (57.1) |
| P value | 0.039 | |
| Treated with DAA | ||
| Before IPTW | ||
| HCV mono-infection (n = 529) | 7 (1.3) | 522 (98.7) |
| HIV/HCV co-infection (n = 56) | 4 (7.1) | 52 (92.9) |
| P value | 0.015 | |
| After IPTW | ||
| HCV mono-infection (n = 529) | 7 (1.3) | 522 (98.7) |
| HIV/HCV co-infection (n = 56) | 2 (3.7) | 54 (96.3) |
| P value | 0.139 | |
- Citation: Park J, Jeong JY, Kim SS, Yoon JH, Eun HS, Choi J, Yoon KT, Jung YK, Park SY, Gwak GY, Kim DY, Kim JH, Lee JW, Kim TY, Jang JW, Yu SJ. Chrono-optimal treatments for human immunodeficiency virus/hepatitis C virus co-infection yield comparable survival outcomes with hepatitis C virus mono-infection. World J Gastroenterol 2026; 32(3): 114176
- URL: https://www.wjgnet.com/1007-9327/full/v32/i3/114176.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i3.114176